Wiregrass Investment Management LLC Buys New Shares in Perrigo Company plc $PRGO

Wiregrass Investment Management LLC purchased a new position in shares of Perrigo Company plc (NYSE:PRGO) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 47,978 shares of the company’s stock, valued at approximately $515,000.

Other hedge funds also recently made changes to their positions in the company. Fuller & Thaler Asset Management Inc. grew its stake in shares of Perrigo by 291.9% during the 4th quarter. Fuller & Thaler Asset Management Inc. now owns 7,824,759 shares of the company’s stock valued at $108,921,000 after buying an additional 5,828,076 shares during the period. Norges Bank acquired a new position in Perrigo in the fourth quarter valued at $42,607,000. Invesco Ltd. boosted its holdings in Perrigo by 134.2% in the fourth quarter. Invesco Ltd. now owns 4,542,415 shares of the company’s stock valued at $63,230,000 after acquiring an additional 2,602,724 shares during the last quarter. ION Fund Management Ltd purchased a new stake in Perrigo during the fourth quarter valued at about $24,499,000. Finally, Vanguard Group Inc. increased its stake in Perrigo by 7.9% during the fourth quarter. Vanguard Group Inc. now owns 14,983,369 shares of the company’s stock worth $208,568,000 after acquiring an additional 1,101,154 shares during the last quarter. Institutional investors and hedge funds own 95.91% of the company’s stock.

Perrigo Trading Down 1.0%

NYSE:PRGO opened at $10.48 on Wednesday. Perrigo Company plc has a 12 month low of $9.23 and a 12 month high of $28.43. The business’s 50-day moving average is $10.64 and its two-hundred day moving average is $11.86. The company has a debt-to-equity ratio of 1.45, a current ratio of 2.72 and a quick ratio of 1.59. The firm has a market capitalization of $1.45 billion, a PE ratio of -0.80, a price-to-earnings-growth ratio of 1.26 and a beta of 0.51.

Perrigo (NYSE:PRGO) last posted its earnings results on Wednesday, May 6th. The company reported $0.43 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.39 by $0.04. The business had revenue of $841.80 million during the quarter, compared to analyst estimates of $1.04 billion. Perrigo had a positive return on equity of 9.96% and a negative net margin of 43.50%.The company’s revenue for the quarter was down 7.2% compared to the same quarter last year. During the same quarter last year, the firm earned $0.60 earnings per share. Perrigo has set its FY 2026 guidance at 2.250-2.550 EPS. Research analysts predict that Perrigo Company plc will post 2.11 earnings per share for the current fiscal year.

Perrigo Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, June 16th. Stockholders of record on Friday, May 29th were paid a $0.29 dividend. The ex-dividend date was Friday, May 29th. This represents a $1.16 annualized dividend and a dividend yield of 11.1%. Perrigo’s dividend payout ratio is -8.85%.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on PRGO shares. Zacks Research raised Perrigo from a “strong sell” rating to a “hold” rating in a research note on Monday, April 27th. Weiss Ratings raised shares of Perrigo from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, June 15th. One analyst has rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $19.33.

Perrigo Profile

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.